

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

INSIDE INFORMATION

RECEIPT OF NON-BINDING PROPOSAL FROM THE CONTROLLING SHAREHOLDER

This announcement is made by MicroPort CardioFlow Medtech Corporation (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) of Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

On July 16, 2025, the board (“**Board**”) of directors of the Company received a non-binding proposal from MicroPort Scientific Corporation (“**MicroPort®**”, together with its subsidiaries, the “**MicroPort® Group**”), the controlling shareholder of the Company, relating to the proposed strategic restructuring of the cardiac rhythm management business of the MicroPort® Group, pursuant to which, subject to further negotiations with interested parties, the execution of definitive agreements and obtaining the necessary consents and approvals, such cardiac rhythm management business will be consolidated with the business of the Group (the “**Proposal**”).

As of the date of this announcement, the Board is still in the process of considering and assessing the Proposal. The Group has been actively exploring suitable opportunities to facilitate the diversification of its product offerings and support its overseas expansion strategy. The Board, with the assistance of independent advisers, will carefully evaluate the merits and reasonableness of the Proposal upon the availability of further details. Should the Proposal be materialized, it may constitute a notifiable transaction and/or a connected transaction of the Company pursuant to Chapter(s) 14 and/or 14A of the Listing Rules, respectively. The Company will make further announcement(s) as and when appropriate and will ensure compliance with all applicable requirements under the Listing Rules.

The Proposal is non-binding, and there is no certainty that the Proposal will proceed or be completed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Company's securities.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Shanghai, PRC, July 16, 2025

As of the date of this announcement, the executive Directors are Mr. Zhang Ruinian, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Mr. Chen Guoming, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan.